An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin

NCT00776659 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2013-11-19

Study results available
· View outcomes & findings →

Summary

To generate the following data from patients with early breast cancer treated with Aromasin® in the adjuvant setting in India.

* Efficacy of the treatment with Aromasin®
* Safety of the treatment with Aromasin®

Conditions

  • Breast Neoplasms

Interventions

OTHER

Aromasin

Non-Interventional study design.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • India

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00776659 on ClinicalTrials.gov